24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Galmed
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:35
“We’re already living in a world where AI is attacking AI”
13:33
“In many cases the first market should not be America”
13:31
“To get Israel to a more precise position in biotech, we need to educate our people to become better managers”
11:51
Could Prompt Security be SentinelOne’s lifeline as shares slide 35% this year?
More stories
Buzz
Most popular
Daily
Weekly
1
“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals
2
Nice puts Actimize up for sale at a $1.5-2 billion price tag
3
Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program
4
Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers
5
Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ
More news
Galmed
4 stories about Galmed
Israeli pharmaceutical company Galmed raises $18 million during trial of its main product
22.02.21
|
James Spiro
The Nasdaq-traded company has developed a drug to treat fatty liver
Biomed at the focus of new Israel-UAE business cooperation
25.10.20
|
CTech
New cross-business initiative is led by Tel-Aviv based consultancy firm Kamir Strategy and UAE-based PR firm Cosmopole
Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering
20.06.18
|
Dror Reich
Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study
Liver Treatment Company Galmed is Raising $6 Million in Direct Offering
04.04.18
|
Lilach Baumer
The company’s stock fell by 37% on Nasdaq since the beginning of the year, and by 66% since its Nasdaq listing in 2014